The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Capturing patient-reported outcomes during the COVID-19 pandemic: Development of the COVID-19 Global Rheumatology Alliance Patient Experience Survey

Arthritis Care Res (Hoboken).

Sirotich E, Dillingham S, Grainger R, Hausmann JS, COVID-19 Global Rheumatology Alliance Steering Committee.

doi: 10.1002/acr.24257.

Psoriasis

Evolution of COVID-19 infection in 4 psoriatic patients treated with biological drugs

J Eur Acad Dermatol Venereol.

Conti A, Lasagni C, Bigi L, Pellacani G

doi: 10.1111/jdv.16587.

Psoriasis

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)

J Am Acad Dermatol.

Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, Goyal K, Lawson F, Langholff W, Hopkins L, Fakharzadeh S, Srivastava B, Menter A

doi: 10.1016/j.jaad.2017.08.051.

Psoriasis

Impact of the COVID-19 pandemic on children with psoriasis

Ann Dermatol Venereol

Beytout Q, Pepiot J, Maruani A, Devulder D, Aubert R, Beylot-Barry M, Amici JM, Jullien D, Mahé E, Association France Psoriasis., Research Group on Psoriasis of the French Society of Dermatology (GrPso)., Research Group of the French Society of Pediatric Dermatology (SFPD).

doi: 10.1016/j.annder.2021.01.005

Allergic Diseases

Considerations on Biologicals for Patients with allergic disease in times of the COVID-19 pandemic: an EAACI Statement

Allergy.

Vultaggio A, Agache I, Akdis CA, Akdis M, Bavbek S, Bossios A, Bousquet J, Boyman O, Chaker AM, Chan S, Chatzipetrou A, Feleszko W, Firinu D, Jutel M, Kauppi P, Klimek L, Kolios A, Kothari A, Kowalski ML, Matucci A, Palomares O, Pfaar O, Rogala B, Untersmayr E, Eiwegger T

doi: 10.1111/all.14407.

Psoriasis

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 2 - Advances in Psoriatic Disease Management, COVID-19 Vaccines, and COVID-19 Treatments

J Am Acad Dermatol

Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V 3rd, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Gondo G, Heydon S, Koons S, Ritchlin CT

doi: 10.1016/j.jaad.2020.12.058

Psoriasis

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1

J Am Acad Dermatol.

Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo RV 3rd, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Smith J, Gondo G, Heydon S, Koons S, Ritchlin CT

doi: 10.1016/j.jaad.2020.09.001.

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs

Semin Arthritis Rheum.

Michelena X, Borrell H, López-Corbeto M, López-Lasanta M, Moreno E, Pascual-Pastor M, Erra A, Serrat M, Espartal E, Antón S, Añez GA, Caparrós-Ruiz R, Pluma A, Trallero-Araguás E, Barceló-Bru M, Almirall M, De Agustín JJ, Segura JL, Julià A, Marsal S

doi: 10.1016/j.semarthrit.

Immunodeficiency

Health-Related-Quality of Life in Common Variable Immunodeficiency Italian patients switched to remote assistance during the COVID-19 pandemic

J Allergy Clin Immunol Pract.

Pulvirenti F, Cinetto F, Milito C, Bonanni L, Pesce AM, Leodori G, Garzi G, Miglionico M, Tabolli S, Quinti I

doi: 10.1016/j.jaip.2020.04.003.

Related content

Capturing patient-reported outcomes during the COVID-19 pandemic: Development of the COVID-19 Global Rheumatology Alliance Patient Experience Survey

Evolution of COVID-19 infection in 4 psoriatic patients treated with biological drugs

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Impact of the COVID-19 pandemic on children with psoriasis

Considerations on Biologicals for Patients with allergic disease in times of the COVID-19 pandemic: an EAACI Statement

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 2 - Advances in Psoriatic Disease Management, COVID-19 Vaccines, and COVID-19 Treatments

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1

Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs

Health-Related-Quality of Life in Common Variable Immunodeficiency Italian patients switched to remote assistance during the COVID-19 pandemic